Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
195 results about "Antibiotic Agents" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Medical Definition of Agent, antibiotic. Agent, antibiotic: A drug used to treat bacterial infections. The original definition of an antibiotic was a substance produced by one microorganism that selectively inhibits the growth of another microorganism.
Antibiotic kit and composition and uses thereof
The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
Owner:VYNE THERAPEUTICS INC
Synthetic, bioabsorbable polymer materials and implants
Owner:BIORETEC
Biofilm formation to define risk for colon cancer
ActiveUS20160223553A1Preventing and diminishing developmentIncreased proliferationMicrobiological testing/measurementUnknown materialsFecesIncreased risk
Methods of identifying subjects at increased risk of cancer, based upon detection of biofilms and / or biofilm-associated microbes within a subject, are disclosed. Therapies designed to prevent formation and / or reduce the size of biofilms in a subject identified to be at increased risk of cancer based upon detection of biofilms and / or biofilm-associated microbes are disclosed. In particular embodiments, the invention provides for identification of a subject at elevated risk of developing or having colorectal cancer and / or a colorectal adenoma, based upon detection of a biofilm and / or biofilm-associated bacteria within the gastrointestinal tract of the subject (optionally, within a biopsy specimen and / or stool sample of such subject). Therapies involving administration of an antibiotic agent and / or a probiotic agent to a subject, to prevent or reduce biofilm formation within the gastrointestinal tract of the subject, optionally provided in combination with additional cancer therapy, are also disclosed.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Method to reduce inflammatory response in transplanted tissue
InactiveUS20050182018A1Inhibit inflammationLower immune responseBiocideSugar derivativesPandrug resistant bacteriaDisease cause
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Combinations of antiseptic and antibiotic agents that inhibit the development of resistant microorganisms
InactiveUS6582719B2Toxic reductionLong-term efficacySuture equipmentsHeavy metal active ingredientsTriclosanChlorhexidine
The present invention relates to compositions comprising a combination of one or more antiseptic and an antibiotic. It is based, at least in part, on the discovery that such combinations tend to deter the formation of antibiotic-resistant organisms. In preferred, nonlimiting embodiments of the invention, the antibiotic is minocycline and the antiseptic is a chlorhexidine compound, triclosan, or benzalkonium chloride, and in particular embodiments, a silver salt or a bismuth salt is added. Examples of specific, nonlimiting embodiments of the invention include combinations of (i) minocycline, triclosan, and a bismuth salt; (ii) minocycline, a chlorhexidine compound, and a bismuth salt; and (iii) minocycline, benzalkonium chloride, and a bismuth salt. The present invention further provides for articles, such as, but not limited to, medical articles, which have been treated with or which otherwise comprise a combination of antiseptic and antibiotic.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Antibiotic Kit and Composition and Uses Thereof
The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
Owner:FOAMIX LTD
Ophthalmic carrier solution
This invention refers to a matter composition of the type used in the treatment of ophthalmic ailments and specifically refers to an ophthalmic carrier solution based on surface-active, emulsifying, antibacterial, antioxidant, etc. Agents which form a carrier that enwraps or masks an active ingredient such as sodium dyclophenac or other antibiotic agents such as tobracin, gentamicin or timolol sulfate, with the aim of avoiding the problems caused by the topical application of the mentioned active ingredients, such as pain, a burning sensation, irritation and other annoyances for the user.
Owner:BAYARDO ARTURO JIMINEZ +1
Antibiotic fiber and preparation method of fiber product
InactiveCN102337602AGood compatibilityAntibacterial long-acting and fastFibre treatmentArtifical filament manufactureAntibiotic AgentsMelt blowing
The invention discloses antibiotic fiber and a preparation method of fiber product. According to the invention, an aqueous nano-grade silver antibiotic agent is prepared into organic nano-grade silver sol by using a chemical phase transferring method, such that the antibiotic agent has a good compatibility with a high polymer substrate; the sol is directly mixed with high polymer, and the mixture is dried, such that an antibiotic high polymer is prepared. The obtained antibiotic high polymer has characteristics of good versatility, good dispensability, simple technology, good processability, good temperature tolerance, and no environmental pollution. With methods of spinning or melt blowing, the antibiotic high polymer can be directly used for preparing antibiotic fibers and antibiotic fiber products. The obtained antibiotic fibers and antibiotic fiber products have excellent performances of rapid and long-lasting antibiotic effect. The physical properties of the antibiotic fibers and the antibiotic fiber products are not changed with additional antibiotic agents.
Owner:周刚
Antibiotic kit and composition and uses thereof
The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
Owner:VYNE THERAPEUTICS INC
Combinations of antiseptic and antibiotic agents containing medical devices
InactiveUS20050192547A1Toxic reductionLong efficacyBiocideDead animal preservationTriclosanChlorhexidine
The present invention relates to compositions comprising a combination of one or more antiseptic and an antibiotic. It is based, at least in part, on the discovery that such combinations tend to deter the formation of antibiotic-resistant organisms. In preferred, nonlimiting embodiments of the invention, the antibiotic is minocycline and the antiseptic is a chlorhexidine compound, triclosan, or benzalkonium chloride, and in particular embodiments, a silver salt or a bismuth salt is added. Examples of specific, nonlimiting embodiments of the invention include combinations of (i) minocycline, triclosan, and a bismuth salt; (ii) minocycline, a chlorhexidine compound, and a bismuth salt; and (iii) minocycline, benzalkonium chloride, and a bismuth salt. The present invention further provides for articles, such as, but not limited to, medical articles, which have been treated with or which otherwise comprise a combination of antiseptic and antibiotic.
Owner:MODAK SHANTA M +2
Face mask structure
InactiveUS20090084384A1Water absorptionEliminate odorBreathing filtersBreathing masksFiberDusting powders
A face mask structure, which includes an outer protective layer prepared from a water-repellent non-woven fabric; an inner protective layer prepared from a hydrophile non-woven fabric; a filter layer prepared from a static high-density fiber material for filtering microbes and dust powder, and sandwiched between the outer and inner protective layers; and a compound layer treated with a multiple functionalize carboxylic acid derivative that is a product from a chemical reaction between a cyclodextrin complex and a multiple functionalize carboxylic acid. The cyclodextrin complex can be a complex of cyclodextrin and an essential oil, antibiotic agent, or mosquito repellent agent.
Owner:CENT HEALTHCARE TECH
Composite antibiotic finishing agent for textiles
ActiveCN105019236AImprove heat resistanceImprove antibacterial propertiesFibre treatmentAntibiotic AgentsBetaine
The invention relates to a composite antibiotic finishing agent for textiles. The composite antibiotic finishing agent for textiles comprises the following raw materials, by weight, 1-5% of polyhexamethylene guanidine, 5-10% of betaine, 1-5% of nano-zinc oxide, 1-5% of chitosan, 0.5-2% of a surfactant, 5-10% of an organic solvent and 0.1-0.5% of essence. With the application of various antibiotic agents for a synergetic antibiotic effect, the composite antibiotic finishing agent for textiles has high heat resistance and strong antibiotic property, is safe and reliable, is green and environmentally friendly, and can be used in antibiotic finish of various textiles.
Owner:江苏神涛环保科技有限公司
Method to reduce inflammatory response in transplanted tissue
InactiveUS7427606B2Lower immune responseGood effectBiocideSugar derivativesResistant bacteriaAntibiotic Agents
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Splinting orthopedic and rehabilitative product
InactiveUS20060051402A1Inhibit microbial growthBiocideInorganic active ingredientsAntibiotic AgentsChemistry
The invention provides a splinting orthopedic or a rehabilitative product that has an increased resistance to odor and / or microbial growth. More particularly, the invention provides for a moldable splinting orthopedic or a rehabilitative product comprising an antibiotic agent and low temperature thermoplastic polymer.
Owner:PATTERSON MEDICAL PRODS
Antibiotic fiber, preparation method thereof and application thereof in home textile
The invention relates to the technical field of textile application, in particular to an antibiotic fiber, a preparation method thereof and an application thereof in home textile, aiming at solving the problem that the prior fiber product is poor in antibiotic effect and can not ensure antibiotic effect. The invention provides an antibiotic fiber which comprises antibiotic agent and fiber, the antibiotic agent at least comprises nano particles which comprises nano titanium dioxide antibiotic agent and Ag ion, the antibiotic agent is added on the fiber by a cross-linking agent to form antibiotic fiber, the antibiotic fiber of the invention has the characteristics of good effect and long lasting time of antibiotic capability.
Owner:SHANGHAI SHUIXING HOME TEXTILE
Compositions and methods for antibiotic potentiation and drug discovery
The present invention provides methods for identifying target genes whose partial or complete functional inactivation potentiates the activity of an antibiotic agent, e.g., a quinolone antibiotic. The invention further provides methods for identifying agents that modulate expression of target genes or that modulate activity of expression products of target genes. Agents identified according to various methods of the invention potentiate the activity of antibiotics such as quinolones, aminoglycosides, peptide antibiotics and β-lactams. Also provided are agents that suppress and / or retard resistance to antibiotics. The inventive methods provide potentiating agents and compositions comprising potentiating agents and antibiotics. Such agents and compositions can be used for inhibiting growth or survival of a microbial cell or of treating a subject suffering from or susceptible to a microbial infection.
Owner:TRUSTEES OF BOSTON UNIV
Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
InactiveUS20050118180A1Enhance immune responseReduce inhibitionBiocideGenetic material ingredientsLeukemiaAbnormal cells
A method for treating diseases associated with abnormal cell proliferation comprises delivering to a patient in need of treatment a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amount of one or more agents selected from the group consisting of alkylating agent, antibiotic agent, an alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and biologic agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases associated with abnormal angiogenesis.
Owner:SUPERGEN
Silver-containing antibacterial viscose fiber and its preparing method
ActiveCN1936124AStrong sterilizationStrong UV protection effectArtificial filaments from viscoseArtifical filament manufactureAntibiotic AgentsFiber
The invention relates to a manufacture method for antibiotic mucilage glue fiber that uses nanometer silver as additive. The method includes the following steps: mixing grains, making glue, spinning, beaming, cutting, refining, drying, packing nanometer silver antibiotic agent; mixing grains, making glue, spinning, beaming, cutting, refining, drying and packing antibiotic mucilage glue fiber. It has the advantages of asepsis, strong antibiotic effect, long effecting time and strong dry-wet rigidity.
Owner:吉林化纤股份有限公司
Gene cluster for biosynthesis of griselimycin and methylgriselimycin
ActiveUS20140295457A1Increase productionEasy to produceBacteriaHydrolasesAntibiotic AgentsGene cluster
The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.
Owner:SANOFI SA
Methods and pharmaceutical compositions for treating sepsis
InactiveUS20060276378A1Promotes therapeutic responseBiocideCarbohydrate active ingredientsAntibiotic AgentsSepsis
Methods and compositions for treating and preventing sepsis are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist in combination with an antibiotic agent. The invention further encompasses pharmaceutical compositions comprising a combination of an A1 adenosine receptor antagonist and an antibiotic agent in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention find use in methods for treating and preventing sepsis.
Owner:ENDACEA
Kernel-shell structured rare-earth nanometer antibiotic agent, prepn. method and application thereof
InactiveCN100998335AGood antibacterial effectEnhanced inhibitory effectBiocideDisinfectantsMinimum inhibitory concentrationRare earth
A nano-class RE antibacterial agent with core-shell structure for plastics, paine and ceramics is prepared from binary RE-heterocyclic compound match composed of RE ions chosen from La, Ce, Pr, Nd, Sm, Er, Eu, Y, Dy and Gd and the heterocyclic compound (imidazole or benzimidazole), and the carrier chosen from spherical SiO2 or spherical meta-porous SiO2. Its preparing process is also disclosed.
Owner:SHANGHAI NORMAL UNIVERSITY
Inorganic antibiotic agent and producing technology
InactiveCN1404732AStable physical and chemical propertiesPure qualityBiocideAnimal repellantsAntibiotic AgentsZinc nitrate
The present invention discloses an inorganic anti-bacterial and anti-midew additive which can be used in the various products of plastic, ceramics, enamels, paints, paper, textile and detergent. It is characterized by that it adopts the bisque powder as main raw material through the following steps: drying said bisque powder, adding water and stirring, adding ammonium nitrate, zinc nitrate and silver nitrate aqueous solution, stirring them, cleaning, filtering, drying and pulverizing so as to obtain the product. It is stable in performance, can resist high-temp. and its production process is simple, low in cost and its application is extensive.
Owner:宋润
Enhancers for microbiological disinfection
InactiveUS6881731B1Increase powerEnhanced inhibitory effectAntibacterial agentsBiocideDisinfectantOrganic dye
Simple carboxylic acids, in particular dicarboxylic acids such as citric acid shows an unexpected ability to enhance the antimicrobial power of a wide range of disinfectant and / or antibiotic agents. As little as 1% citrate greatly enhances the ability of antibiotics to kill or inhibit a wide range of bacterial species including antibiotic resistant strains. Citrate alone is effective in preventing bacterial growth in platelet concentrates and in red blood cell suspensions. Effective concentrations of citrate cause little if any damage to blood cells. Besides enhancing the power of antibiotics citrate also enhances the antimicrobial properties of disinfectant organic dyes such as crystal violet and methylene blue. In addition citrate enhances the antimicrobial properties of polyphenols of plant origin. Iodine-based disinfectants are also enhanced without enhancing protein denaturation.
Owner:SHANBROM TECH
Cosmetic preparations with anitacterial properties
Disclosed are cosmetic preparations and, more particularly, skin and hair care and cleaning products with an amount of at least one glycyrrhetic antibacterial agent selected from glycyrrhetic acid, glycyrrhetic acid derivatives and extracts of Glycyrrhiza glabra, and their salts, effective to inhibit or prevent the growth of bacteria. The cosmetic preparations may include other antibacterial or antibiotic agents. The glycyrrhetic antibacterial agent and, optionally, the antibacterial or antibiotic agents may be provided in microencapsulated form. Also disclosed is the use of such cosmetic preparations for treating acne.
Owner:COGNIS DEUT GMBH & CO KG
Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
An oral rinse formulation for the treatment or prophylaxis of mucositis or stomatitis comprises one or more of the following components in combination with pharmaceutically acceptable excipients or additives: a) at least one corticosteroid; b) at least one anti-histamine; c) at least one topical anaesthetic; and, d) at least one anti-fungal antibiotic agent. A stable nystatin containing formulation is also provided comprising a buffering agent, a preservative, a chelating agent and an anti-oxidant.
Owner:MYREX PHARMA
Silicibacter sp. strain useful for genetic transformation of marine algae and production of antibiotic agents
InactiveUS20090142429A1Inhibition of attachmentEliminate needAntibacterial agentsBiocideAntibiotic AgentsVibrio anguillarum
A Silicibacter sp. strain useful for genetic transformation of marine algae and production of antibiotic agents is described. Silicibacter sp. TM1040 is a genetically tractable member of the marine Roseobacter clade of bacteria that forms an intimate and obligate interaction with algae, and is useful as a probiotic for producing antibacterial agents that are cidally effective against pathogenic bacteria such as Mycobacterium marinum, Vibrio anguillarum, V. coralliilyticus, and V. shiloi bacteria.
Owner:UNIV OF MARYLAND BALTIMORE COUNTY
Polymers having covalently bound antibiotic agents
An antimicrobial composition comprising: a complex of a polysaccharide covalently bonded with an antibiotic. A medical device having an antimicrobial composition comprising: a complex of an oxidized regenerated cellulose covalently bonded with gentamicin.
Owner:ETHICON INC
Mildew resistant antimicrobial type low corrosion water-based scaling powder
InactiveCN101239428AInhibit growthDoes not cause corrosionWelding/cutting media/materialsSoldering mediaWater basedActive agent
The invention relates to soldering fluid technique, which is a modified technique based on prior art, specifically relates to a mildew resistant antibiotic low-corrosivity water-based soldering fluid, comprising components with following percentage by weight (): 1.0% of active agent, 1.0% of micro-enwrapping agent, 0.1% of surfactant, 0.01% of mildew resistant antibiotic agent, residue is solvent of de-ionized water, and the weight sum of each components are 100 The advantages of the invention are: the soldering fluid contains no volatile organic matter or halide, and can inhibit development of microorganisms such as bacteria and fungi and mildew; circuit and conveyor are not eroded during welding, no cleaning is needed after welded, and the soldering fluid is safe and environmentally-friendly; the soldering fluid can be coated on the PCB plate weld face by spraying, dipping or foaming mode to implement leadless welding of electronic products. The invented soldering fluid is practical and has great market potential.
Owner:PERFECTION SCI & TECH DONGGUAN
Erythromycin derivatives as antibacterial agents
InactiveCN101103039AOrganic active ingredientsSugar derivativesAntibiotic AgentsMacrolide resistance
This invention relates to a novel class of antibiotic agents, more specifically to macrolides comprising an oxazolidinone structure, their preparation, pharmaceutical compositions containing them, their use and methods of treatment using them.
Owner:ALPHARMA AS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com